Original articles
Xiaokui Huo, Qiang Meng, Changyuan Wang, Yanna Zhu, Zhihao Liu, Xiaodong Ma, Xiaochi Ma, Jinyong Peng, Huijun Sun, Kexin Liu. Cilastatin protects against imipenem-induced nephrotoxicity via inhibition of renal organic anion transporters (OATs)[J]. Acta Pharmaceutica Sinica B, 2019, 9(5): 986-996

Cilastatin protects against imipenem-induced nephrotoxicity via inhibition of renal organic anion transporters (OATs)
Xiaokui Huoa,b,c, Qiang Menga,b,c, Changyuan Wanga,b,c, Yanna Zhua, Zhihao Liua, Xiaodong Maa, Xiaochi Maa,b,c, Jinyong Penga,b,c, Huijun Suna,b,c, Kexin Liua,b,c
a Department of Clinical Pharmacology, College of Pharmacy, Dalian Medical University, Dalian 116044, China;
b College(Institute) of Integrative Medicine, Dalian Medical University, Dalian 116044, China;
c Provincial Key Laboratory for Pharmacokinetics and Transport, Dalian Medical University, Dalian 116044, China
Imipenem is a carbapenem antibiotic. However, Imipenem could not be marketed owing to its instability and nephrotoxicity until cilastatin, an inhibitor of renal dehydropeptidase-I (DHP-I), was developed. In present study, the potential roles of renal organic anion transporters (OATs) in alleviating the nephrotoxicity of imipenem by cilastatin were investigated in vitro and in rabbits. Our results indicated that imipenem and cilastatin were substrates of hOAT1 and hOAT3. Cilastatin inhibited hOAT1/3-mediated transport of imipenem with IC50 values comparable to the clinical concentration, suggesting the potential to cause a clinical drug-drug interaction (DDI). Moreover, imipenem exhibited hOAT1/3-dependent cytotoxicity, which was alleviated by cilastatin and probenecid. Furthermore, cilastatin and probenecid ameliorated imipenem-induced rabbit acute kidney injury, and reduced the renal secretion of imipenem. Cilastatin and probenecid inhibited intracellular accumulation of imipenem and sequentially decreased the nephrocyte toxicity in rabbit primary proximal tubule cells. Renal OATs, besides DHP-I, was also the target of interaction between imipenem and cilastatin, and contributed to the nephrotoxicity of imipenem. This therefore gives in part the explanation about the mechanism by which cilastatin protected against imipenem-induced nephrotoxicity. Thus, OATs can potentially be used as a therapeutic target to avoid the renal adverse reaction of imipenem in clinic.
Key words:    Imipenem    Cilastatin    Probenecid    OATs    hOAT1    hOAT3    Nephrotoxicity   
Received: 2018-11-02     Revised: 2018-11-29
DOI: 10.1016/j.apsb.2019.02.005
Funds: The work was supported by a grant from the National Natural Science Foundation of China, China (Nos. 81874324, 81473280, and U1608283) and Dalian Science and technology innovation found, China (No. 2018J12SN065). The authors thank Prof. Yuichi Sugiyama (Sugiyama Laboratory, RIKEN, Japan) for kindly providing Mock/hOAT1/3-HEK293 cells.
Corresponding author: Kexin Liu     Email:kexinliu@dlmedu.edu.cn
Author description:
PDF(KB) Free
Xiaokui Huo
Qiang Meng
Changyuan Wang
Yanna Zhu
Zhihao Liu
Xiaodong Ma
Xiaochi Ma
Jinyong Peng
Huijun Sun
Kexin Liu

1. Balfour JA, Bryson HM, Brogden RN. Imipenem/cilastatin:an update of its antibacterial activity, pharmacokinetics and therapeutic efficacy in the treatment of serious infections. Drugs 1996;51:99-136.
2. Papp-Wallace KM, Endimiani A, Taracila MA, Bonomo RA. Carbapenems:past, present, and future. Antimicrob Agents Chemother 2011;55:4943-60.
3. Kropp H, Sundelof JG, Hajdu R, Kahan FM. Metabolism of thienamycin and related carbapenem antibiotics by the renal dipeptidase, dehydropeptidase. Antimicrob Agents Chemother 1982;22:62-70.
4. Graham DW, Ashton WT, Barash L, Brown JE, Brown RD, Canning LF, et al. Inhibition of the mammalian β-lactamase renal dipeptidase (dehydropeptidase-i) by (z)-2-(acylamino)-3-substituted-propenoic acids. J Med Chem 1987;30:1074-90.
5. Tune BM, Hsu CY. The renal mitochondrial toxicity of β-lactam antibiotics:in vitro effects of cephaloglycin and imipenem. J Am Soc Nephrol 1990;1:815-21.
6. Tune BM, Fravert D, Hsu CY. Thienamycin nephrotoxicity. Mitochondrial injury and oxidative effects of imipenem in the rabbit kidney. Biochem Pharmacol 1989;38:3779-83.
7. Sack K, Herhahn J, Marre R, Schulz E. Renal tolerance of imipenem/cilastatin and other β-lactam antibiotics in rats. Infection 1985;13 Suppl 1:S156-60.
8. Norrby SR, Alestig K, Bjornegard B, Burman LA, Ferber F, Huber JL, et al. Urinary recovery of n-formimidoyl thienamycin (MK0787) as affected by coadministration of n-formimidoyl thienamycin dehydropeptidase inhibitors. Antimicrob Agents Chemother 1983;23:300-7.
9. Birnbaum J, Kahan FM, Kropp H, MacDonald JS Carbapenems. a new class of β-lactam antibiotics. Discovery and development of imipenem/cilastatin. Am J Med 1985;78:3-21.
10. Zhanel GG, Simor AE, Vercaigne L, Mandell L. Imipenem and meropenem:comparison of in vitro activity, pharmacokinetics, clinical trials and adverse effects. Can J Infect Dis 1998;9:215-28.
11. Hornik CP, Herring AH, Benjamin Jr. DK, Capparelli EV, Kearns GL, van den Anker J, et al. Adverse events associated with meropenem versus imipenem/cilastatin therapy in a large retrospective cohort of hospitalized infants. Pediatr Infect Dis J 2013;32:748-53.
12. Tejedor A, Torres AM, Castilla M, Lazaro JA, de Lucas C, Caramelo C. Cilastatin protection against cyclosporin A-induced nephrotoxicity:clinical evidence. Curr Med Res Opin 2007;23:505-13.
13. Humanes B, Lazaro A, Camano S, Moreno-Gordaliza E, Lazaro JA, Blanco-Codesido M, et al. Cilastatin protects against cisplatin-induced nephrotoxicity without compromising its anticancer efficiency in rats. Kidney Int 2012;82:652-63.
14. Nakamura T, Hashimoto Y, Kokuryo T, Inui KI. Effects of fosfomycin and imipenem/cilastatin on nephrotoxicity and renal excretion of vancomycin in rats. Pharm Res 1998;15:734-8.
15. Camano S, Lazaro A, Moreno-Gordaliza E, Torres AM, de Lucas C, Humanes B, et al. Cilastatin attenuates cisplatin-induced proximal tubular cell damage. J Pharmacol Exp Ther 2010;334:419-29.
16. Perez M, Castilla M, Torres AM, Lazaro JA, Sarmiento E, Tejedor A. Inhibition of brush border dipeptidase with cilastatin reduces toxic accumulation of cyclosporin a in kidney proximal tubule epithelial cells. Nephrol Dial Transplant 2004;19:2445-55.
17. Moreno-Gordaliza E, Giesen C, Lazaro A, Esteban-Fernandez D, Humanes B, Canas B, et al. Elemental bioimaging in kidney by LA-ICP-MS as a tool to study nephrotoxicity and renal protective strategies in cisplatin therapies. Anal Chem 2011;83:7933-40.
18. Yin J, Wang J. Renal drug transporters and their significance in drug-drug interactions. Acta Pharm Sin B 2016;6:363-73.
19. Huo X, Liu K. Renal organic anion transporters in drug-drug interactions and diseases. Eur J Pharm Sci 2018;112:8-19.
20. Hsueh CH, Yoshida K, Zhao P, Meyer TW, Zhang L, Huang SM, et al. Identification and quantitative assessment of uremic solutes as inhibitors of renal organic anion transporters, OAT1 and OAT3. Mol Pharm 2016;13:3130-40.
21. Sun CY, Wu MS, Lee CC, Chen SH, Lo KC, Chen YH. A novel SNP in the 50 regulatory region of organic anion transporter 1 is associated with chronic kidney disease. Sci Rep 2018;8:8085.
22. Jia Y, Liu Z, Wang C, Meng Q, Huo X, Liu Q, et al. P-gp, MRP2 and OAT1/OAT3 mediate the drug-drug interaction between resveratrol and methotrexate. Toxicol Appl Pharmacol 2016;306:27-35.
23. Liu Q, Wang C, Meng Q, Huo X, Sun H, Peng J, et al. Mdr1 and OAT1/OAT3 mediate the drug-drug interaction between puerarin and methotrexate. Pharm Res 2014;31:1120-32.
24. Liu Z, Jia Y, Wang C, Meng Q, Huo X, Sun H, et al. Organic anion transporters 1(OAT1) and OAT3 meditated the protective effect of rhein on methotrexate-induced nephrotoxicity. RSC Adv 2017;7:25461-8.
25. Alexander LD, Alagarsamy S, Douglas JG. Cyclic stretch-induced cPLA2 mediates ERK 1/2 signaling in rabbit proximal tubule cells. Kidney Int 2004;65:551-63.
26. Li LP, Song FF, Weng YY, Yang X, Wang K, Lei HM, et al. Role of OCT2 and MATE1 in renal disposition and toxicity of nitidine chloride. Br J Pharmacol 2016;173:2543-54.
27. Huo X, Wang C, Yu Z, Peng Y, Wang S, Feng S, et al. Human transporters, PEPT1/2, facilitate melatonin transportation into mitochondria of cancer cells:an implication of the therapeutic potential. J Pineal Res 2017;62:12390.
28. Shiba K, Saito A, Shimada J, Hori S, Kaji M, Miyahara T, et al. Renal handling of fleroxacin in rabbits, dogs, and humans. Antimicrob Agents Chemother 1990;34:58-64.
29. Kim JM, Ha JR, Oh SW, Kim HG, Lee JM, Kim BO, et al. Comparison of in vivo nephrotoxicity in the rabbit by a pyrrolidinyl-thio carbapenem CW-270031. J Microbiol Biotechnol 2008;18:1768-72.
30. Kulkarni MV, Zurita AN, Pyka JS, Murray TS, Hodsdon ME, Peaper DR. Use of imipenem to detect KPC, NDM, OXA, IMP, and VIM carbapenemase activity from Gram-negative rods in 75 minutes using liquid chromatography-tandem mass spectrometry. J Clin Microbiol 2014;52:2500-5.
31. Verwaest C. Meropenem versus imipenem/cilastatin as empirical monotherapy for serious bacterial infections in the intensive care unit. Clin Microbiol Infect 2000;6:294-302.
32. Vazquez JA, Gonzalez Patzan LD, Stricklin D, Duttaroy DD, Kreidly Z, Lipka J, et al. Efficacy and safety of ceftazidime-avibactam versus imipenem-cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults:results of a prospective, investigator-blinded, randomized study. Curr Med Res Opin 2012;28:1921-31.
33. Hayashi Y, Roberts JA, Paterson DL, Lipman J. Pharmacokinetic evaluation of piperacillin-tazobactam. Expert Opin Drug Metab Toxicol 2010;6:1017-31.
34. Wen S, Wang C, Duan Y, Huo X, Meng Q, Liu Z, et al. OAT1 and OAT3 also mediate the drug-drug interaction between piperacillin and tazobactam. Int J Pharm 2018;537:172-82.
35. Lepist EI, Zhang X, Hao J, Huang J, Kosaka A, Birkus G, et al. Contribution of the organic anion transporter OAT2 to the renal active tubular secretion of creatinine and mechanism for serum creatinine elevations caused by cobicistat. Kidney Int 2014;86:350-7.
36. Gordon LA, Kumar P, Brooks KM, Kellogg A, McManus M, Alfaro RM, et al. Antiretroviral boosting agent cobicistat increases the pharmacokinetic exposure and anticoagulant effect of dabigatran in HIV-negative healthy volunteers. Circulation 2016;134:1909-11.
37. Takeda M, Narikawa S, Hosoyamada M, Cha SH, Sekine T, Endou H. Characterization of organic anion transport inhibitors using cells stably expressing human organic anion transporters. Eur J Pharmacol 2001;419:113-20.
38. Enomoto A, Takeda M, Tojo A, Sekine T, Cha SH, Khamdang S, et al. Role of organic anion transporters in the tubular transport of indoxyl sulfate and the induction of its nephrotoxicity. J Am Soc Nephrol 2002;13:1711-20.
39. Feng B, Varma MV. Evaluation and quantitative prediction of renal transporter-mediated drug-drug interactions. J Clin Pharmacol 2016;56 Suppl 7:S110-21.
40. Morrissey KM, Stocker SL, Wittwer MB, Xu L, Giacomini KM. Renal transporters in drug development. Annu Rev Pharmacol Toxicol 2013;53:503-29.
41. Markowitz GS, Bomback AS, Perazella MA. Drug-induced glomerular disease:direct cellular injury. Clin J Am Soc Nephrol 2015;10:1291-9.
42. Mehta RL, Pascual MT, Soroko S, Savage BR, Himmelfarb J, Ikizler TA, et al. Spectrum of acute renal failure in the intensive care unit:the PICARD experience. Kidney Int 2004;66:1613-21.
43. Nigam SK. What do drug transporters really do?. Nat Rev Drug Discov 2015;14:29-44.
44. Wang L, Sweet DH. Renal organic anion transporters (SLC22 family):expression, regulation, roles in toxicity, and impact on injury and disease. AAPS J 2013;15:53-69.
45. Hirouchi Y, Naganuma H, Kawahara Y, Okada R, Kamiya A, Inui K, et al. Preventive effect of betamipron on nephrotoxicity and uptake of carbapenems in rabbit renal cortex. Jpn J Pharmacol 1994;66:1-6.
46. Bassetti M, Nicolini L, Esposito S, Righi E, Viscoli C. Current status of newer carbapenems. Curr Med Chem 2009;16:564-75.
47. Yousif T, Pooyeh S, Hannemann J, Baumann J, Tauber R, Baumann K. Nephrotoxic and peroxidative potential of meropenem and imipenem/cilastatin in rat and human renal cortical slices and microsomes. Int J Clin Pharmacol Ther 1999;37:475-86.
48. Cannella CA, Wilkinson ST. Acute renal failure associated with inhaled tobramycin. Am J Health Syst Pharm 2006;63:1858-61.